| The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer P Goldstraw, K Chansky, J Crowley, R Rami-Porta, H Asamura, ... Journal of Thoracic Oncology 11 (1), 39-51, 2016 | 4537 | 2016 |
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer M Fukuoka, S Yano, G Giaccone, T Tamura, K Nakagawa, JY Douillard, ... Journal of clinical oncology 21 (12), 2237-2246, 2003 | 3994 | 2003 |
| Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 2 RS Herbst, G Giaccone, JH Schiller, RB Natale, V Miller, C Manegold, ... Journal of Clinical Oncology 22 (5), 785-794, 2004 | 2335 | 2004 |
| Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 1 G Giaccone, RS Herbst, C Manegold, G Scagliotti, R Rosell, V Miller, ... Journal of Clinical Oncology 22 (5), 777-784, 2004 | 2313 | 2004 |
| Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists … NI Lindeman, PT Cagle, MB Beasley, DA Chitale, S Dacic, G Giaccone, ... Journal of Thoracic Oncology 8 (7), 823-859, 2013 | 2007 | 2013 |
| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ... Jama 311 (19), 1998-2006, 2014 | 1904 | 2014 |
| Targeting the dynamic HSP90 complex in cancer J Trepel, M Mollapour, G Giaccone, L Neckers Nature reviews cancer 10 (8), 537-549, 2010 | 1764 | 2010 |
| Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas, A Szczésna, E Juhász, ... The lancet oncology 11 (6), 521-529, 2010 | 1593 | 2010 |
| Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC RS Herbst, G Giaccone, F de Marinis, N Reinmuth, A Vergnenegre, ... New England Journal of Medicine 383 (14), 1328-1339, 2020 | 1453 | 2020 |
| Cell death independent of caspases: a review LE Broker, FAE Kruyt, G Giaccone Clinical Cancer Research 11 (9), 3155-3162, 2005 | 1329 | 2005 |
| American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer CG Azzoli, S Baker Jr, S Temin, W Pao, T Aliff, J Brahmer, DH Johnson, ... Journal of clinical oncology 27 (36), 6251-6266, 2009 | 990 | 2009 |
| Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non–small-cell lung cancer GV Scagliotti, R Fossati, V Torri, L Crino, G Giaccone, G Silvano, ... Journal of the National Cancer Institute 95 (19), 1453-1461, 2003 | 835 | 2003 |
| Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non–small-cell lung cancer JP Van Meerbeeck, GWPM Kramer, PEY Van Schil, C Legrand, EF Smit, ... Journal of the National Cancer Institute 99 (6), 442-450, 2007 | 830 | 2007 |
| American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non … VL Keedy, S Temin, MR Somerfield, MB Beasley, DH Johnson, ... Journal of clinical oncology 29 (15), 2121-2127, 2011 | 811 | 2011 |
| Epidermal growth factor receptor mutations and gene amplification in non–small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials DW Bell, TJ Lynch, SM Haserlat, PL Harris, RA Okimoto, BW Brannigan, ... Journal of Clinical Oncology 23 (31), 8081-8092, 2005 | 748 | 2005 |
| Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for … JP van Meerbeeck, R Gaafar, C Manegold, RJ Van Klaveren, ... Journal of Clinical Oncology 23 (28), 6881-6889, 2005 | 733 | 2005 |
| Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update N Hanna, D Johnson, S Temin, S Baker Jr, J Brahmer, PM Ellis, ... Journal of Clinical Oncology 35 (30), 3484-3515, 2017 | 718 | 2017 |
| A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors G Giaccone, CJA Punt, Y Ando, R Ruijter, N Nishi, M Peters, ... Clinical Cancer Research 8 (12), 3702-3709, 2002 | 701 | 2002 |
| The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth … WD Travis, H Asamura, AA Bankier, MB Beasley, F Detterbeck, DB Flieder, ... Journal of Thoracic Oncology 11 (8), 1204-1223, 2016 | 685 | 2016 |
| Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer CM Rudin, CL Hann, EB Garon, M Ribeiro de Oliveira, PD Bonomi, ... Clinical Cancer Research 18 (11), 3163-3169, 2012 | 650 | 2012 |
